<DOC>
	<DOCNO>NCT01682863</DOCNO>
	<brief_summary>This study ass safety tolerability two different dos QVA149 QAB149 patient moderate severe airflow limitation .</brief_summary>
	<brief_title>A Multi-centre Randomized Double Blind 52-week Study Assess Safety QVA149 Compared QAB149 Patients With COPD Who Have Moderate Severe Airflow Limitation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female adult age ≥40 year Patients stable COPD accord GOLD strategy ( GOLD 2011 ) . Patients airflow limitation indicate postbronchodilator FEV1 ≥ 30 % &lt; 80 % predict normal , postbronchodilator FEV1/FVC &lt; 0.70 . Current exsmokers smoke history least 10 pack year . Patients mMRC ≥ grade 2 History long QT syndrome prolong QTc Patients COPD exacerbation require treatment antibiotic and/or systemic corticosteroid and/or hospitalization 6 week prior Visit 1 . Patients Type I uncontrolled Type II diabetes Patients history asthma concomitant pulmonary disease Patients paroxysmal ( e.g . intermittent ) atrial fibrillation . Only patient persistent atrial fibrillation control rate control strategy least six month could eligible Patients clinically significant renal , cardiovascular , neurological , endocrine , immunological , psychiatric , gastrointestinal , hepatic , hematological abnormality could interfere assessment safety Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD , QAB149 , QVA149 , indacaterol maleate , gylcopyrronium bromide</keyword>
</DOC>